{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:00:48Z","timestamp":1758816048105,"version":"3.40.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00280-014-2445-5","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T13:48:44Z","timestamp":1395928124000},"page":"1119-1127","source":"Crossref","is-referenced-by-count":9,"title":["An evaluation of the potential for drug\u2013drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1007","volume":"73","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Hellriegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Philmore","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luann","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela C.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"issue":"1","key":"2445_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317","journal-title":"Clin Cancer Res"},{"key":"2445_CR2","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","volume":"27","author":"WU Knauf","year":"2009","unstructured":"Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378\u20134384","journal-title":"J Clin Oncol"},{"key":"2445_CR3","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"2445_CR4","unstructured":"(2012) Treanda [package insert]. Cephalon, Inc., Frazer, PA"},{"key":"2445_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975\u2013980","journal-title":"Blood"},{"key":"2445_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423","journal-title":"Blood"},{"key":"2445_CR7","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, W\u00f6rmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Tr\u00fcmper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"2445_CR8","unstructured":"(2012) Rituxan [package insert]. Genentech, Inc., South San Francisco, CA"},{"key":"2445_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11319980-000000000-00000","volume":"49","author":"JI Lee","year":"2010","unstructured":"Lee JI, Zhang L, Men AY, Kenna LA, Huang SM (2010) CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49:295\u2013310","journal-title":"Clin Pharmacokinet"},{"key":"2445_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1080\/10428190701472021","volume":"48","author":"F Bertoni","year":"2007","unstructured":"Bertoni F, Zucca E (2007) Bendamustine in lymphomas: more to combine? Leuk Lymphoma 48:1264\u20131266","journal-title":"Leuk Lymphoma"},{"key":"2445_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1208\/s12248-011-9285-6","volume":"13","author":"S Girish","year":"2011","unstructured":"Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, Evers R, Zhou H, Zhu M, Klunk L, Han C, Berglund EG, Huang SM, Joshi A (2011) AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J 13:405\u2013416","journal-title":"AAPS J"},{"key":"2445_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","volume":"132","author":"M Herold","year":"2006","unstructured":"Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, M\u00fcller C, M\u00fcller C, East German Study Group Hematology Oncology (OSHO) (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 132:105\u2013112","journal-title":"J Cancer Res Clin Oncol"},{"key":"2445_CR13","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/17425255.2012.723690","volume":"8","author":"A Korycka-Wolowiec","year":"2012","unstructured":"Korycka-Wolowiec A, Robak T (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 8:1455\u20131468","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2445_CR14","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, D\u00fcrk H, Rost A, Neise M, von Gr\u00fcnhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:3383\u20133389","journal-title":"J Clin Oncol"},{"key":"2445_CR15","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","volume":"22","author":"E Weidmann","year":"2011","unstructured":"Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, J\u00e4ger E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80\u00a0years or older with aggressive B-cell lymphomas. Ann Oncol 22:1839\u20131844","journal-title":"Ann Oncol"},{"key":"2445_CR16","doi-asserted-by":"publisher","unstructured":"Rummel MJ, Niederle N, Maschmeyher G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab (BR) versus CHOP plus rituximab (CHOP-R) as first-line treatment for patients with indolent and mantle cell lymphomas: an open-label, multicentre, randomized, phase 3 non-inferiority trial. Lancet. doi: 10.1016\/S0140-6736(12)61763-2","DOI":"10.1016\/S0140-6736(12)61763-2"},{"issue":"4 Suppl 13","key":"2445_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/sonc.2002.34873","volume":"29","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E (2002) In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 29(4 Suppl 13):12\u201314","journal-title":"Semin Oncol"},{"key":"2445_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","volume":"66","author":"JS Owen","year":"2010","unstructured":"Owen JS, Melhem M, Passarell JA, D\u2019Andrea D, Darwish M, Kahl B (2010) Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin\u2019s lymphoma. Cancer Chemother Pharmacol 66:1039\u20131049","journal-title":"Cancer Chemother Pharmacol"},{"key":"2445_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493\u2013507","journal-title":"Clin Pharmacokinet"},{"key":"2445_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/0091270007306958","volume":"47","author":"K Seitz","year":"2007","unstructured":"Seitz K, Zhou H (2007) Pharmacokinetic drug\u2013drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 47:1104\u20131118","journal-title":"J Clin Pharmacol"},{"key":"2445_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","volume":"11","author":"MA Tabrizi","year":"2006","unstructured":"Tabrizi MA, Tseng C-ML, Rosikos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81\u201388","journal-title":"Drug Discov Today"},{"key":"2445_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1399-0012.1997.tb00778.x","volume":"11","author":"EM Vasquez","year":"1997","unstructured":"Vasquez EM, Pollak R (1997) OKT3 therapy increases cyclosporine blood levels. Clin Transplant 11:38\u201341","journal-title":"Clin Transplant"},{"key":"2445_CR23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S0140-6736(00)02822-1","volume":"356","author":"J Strehlau","year":"2000","unstructured":"Strehlau J, Pape L, Offner G, Nashan B, Ehrich JH (2000) Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 356:1327\u20131328","journal-title":"Lancet"},{"key":"2445_CR24","first-page":"2347","volume":"31","author":"A Bunescu","year":"2004","unstructured":"Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N (2004) Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31:2347\u20132355","journal-title":"J Rheumatol"},{"key":"2445_CR25","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1016\/S0021-9258(18)60482-X","volume":"264","author":"JJ Enghild","year":"1989","unstructured":"Enghild JJ, Salvesen G, Th\u00f8gersen IB, Pizzo SV (1989) Proteinase binding and inhibition by the monomeric alpha-macroglobulin rat alpha 1-inhibitor-3. J Biol Chem 264:11428\u201311435","journal-title":"J Biol Chem"},{"key":"2445_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","volume":"23","author":"H Blasco","year":"2009","unstructured":"Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le Guellec C (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin\u2019s lymphoma. Fundam Clin Pharmacol 23:601\u2013608","journal-title":"Fundam Clin Pharmacol"},{"key":"2445_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","volume":"62","author":"G Cartron","year":"2007","unstructured":"Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C (2007) Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 62:43\u201352","journal-title":"Crit Rev Oncol Hematol"},{"key":"2445_CR28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116:106\u2013114","journal-title":"Cancer"},{"key":"2445_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M (2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27:785\u2013792","journal-title":"Ther Drug Monit"},{"key":"2445_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D (1998) Association of serum rituximab (IDEC\u2013C2B8) concentration and anti-tumor response in the treatment of recurrent low\u2013grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 9:995\u20131001","journal-title":"Ann Oncol"},{"key":"2445_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2141.2002.03256.x","volume":"116","author":"M Lazzarino","year":"2002","unstructured":"Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E (2002) A sequence of immunochemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116:229\u2013235","journal-title":"Br J Haematol"},{"key":"2445_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","volume":"22","author":"I Iacona","year":"2000","unstructured":"Iacona I, Lazzarino M, Avanzini MA, Rupolo M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB (2000) Rituximab (IDEC\u2013C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 22:295\u2013301","journal-title":"Ther Drug Monit"},{"key":"2445_CR33","unstructured":"Holford N (2005) VPC, the visual predictive check-superiority to standard diagnostic (Rorschach) plots. Population Approach Group in Europe: [abstract 738]"},{"key":"2445_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/j.1349-7006.2011.01994.x","volume":"102","author":"M Ogura","year":"2011","unstructured":"Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K, Japanese Bendamustine Lymphoma Study Group (2011) Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin\u2019s lymphoma. Cancer Sci 102:1687\u20131692","journal-title":"Cancer Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2445-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2445-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2445-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T05:25:17Z","timestamp":1746163517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2445-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2445"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2445-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}